Spotlight on infliximab in Crohn disease and rheumatoid arthritis

BioDrugs

Volumn 20, Issue 1, 2006, Pages 67-70

  Siddiqui, M Asif A ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEART FAILURE; HUMAN; INFECTION; LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; COSTS AND COST ANALYSIS; CROHN DISEASE; HUMANS;

EID: 33645542838     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620010-00008     Document Type: Review

References (37)

1. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30 (16): 1443-53
2. van den Brande JMH, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn's disease. J Rheumatol Suppl 2005 Mar; 74: 26-30
3. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 2002; 16 (2): 111-48
4. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001 Apr; 15 (4): 463-73
5. Centocor Inc. Product information (US): Remicade for IV injection (infliximab 100mg vial) [online]. Available from URL: http://www.remicade.com [Accessed 2005 May 10]
6. Centocor B.V. Product information (EU): Remicade 100mg powder for concentrate for solution for infusion (infliximab 100mg vial) [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2005 May 10]
7. Boyle A, Tawadros R, Zhu Y, et al. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn's disease patients. Gastroenterology 2002 Apr; 122 Suppl. 1: A614-5. Plus poster presented at Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association; 2002 May 19-23; San Francisco (CA)
8. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000 Apr; 27 (4): 841-50
9. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999 Oct; 117 (4): 761-9
10. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 Apr; 50 (4): 1051-65
11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factora monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41 (9): 1552-63
12. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003 Apr; 98: 833-8
13. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 Nov 30; 343 (22): 1594-602
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 May 4; 359: 1541-9
15. St. Clair EW, van der Heijde DMFM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomised controlled trial. Arthritis Rheum 2004 Nov; 50 (11): 3432-43
16. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337 (15): 1029-35
17. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002 Apr; 29: 667-77
18. D'haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999 May; 116 (5): 1029-34
19. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 Oct; 98 (10): 2232-8
20. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 Feb 26; 350 (9): 876-85
21. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004 May; 36 (5): 342-7
22. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003 May; 36 (5): 632-6
23. deRidder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004 Jul; 39 (1): 46-52
24. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 Dec 4; 354 (9194): 1932-9
25. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Jan; 52 (1): 27-35
26. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004 Apr; 50 (4): 1107-16
27. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor alpha antagonists. Drug Saf 2004; 27 (5): 307-24
28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001 Oct 21; 345 (15): 1098-104
29. Geborek P, Bladstrom A, Turesson C, et al. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005; 64 (5): 699-703
30. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 May 20; 138 (10): 807-11
31. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44 (12): 2862-9
32. Bodger K. Economic implications of biological therapies for Crohn's Disease: review of infliximab. Pharmacoeconomics 2005; 23 (9): 875-88
33. Wong JB, Loftus Jr EV, Sandborn WJ, et al. Estimating the cost-effectiveness of infliximab for Crohn's disease [abstract no. G0451]. Gastroenterology 1999 Apr; 116 (4 Pt 2): 104-5
34. Wong JB, Loftus EV, Sandborn WJ, et al. A cost-effectiveness analysis of maintenance infliximab for chronic active Crohn's disease in Canada [abstract no. G398]. Gut 2004; 53 Suppl. 6: 232
35. Colombel JF, Rutgeerts P, Yan S, et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients [abstract no. W1344]. Gastroenterology 2002 Apr; 122 Suppl. 1: A613
36. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005 Apr; 128 (4): 862-9
37. Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22 (2): 107-32